Following completion of her postdoctoral training, Dr. Haigwood spent 17 years in the biotechnology and pharmaceutical sector, principally at Chiron Corporation (Novartis) in Emeryville, California, and at the Bristol-Myers Squibb Pharmaceutical Research Institute in Seattle, Washington. From 1997-2007, she was a Professor of Microbiology and Pathobiology at the University of Washington and Member at the Center for Infectious Disease Research, both in Seattle. Since 1986, the focus of her research has been on HIV and AIDS, with a focus on halting mother to child transmission and on vaccines for children and adults. She was recruited to OHSU in 2007 to become the fifth director of the Oregon National Primate Research Center and to continue an active research program. Currently, Dr. Haigwood serves as a volunteer board member for the local AIDS service organization in Portland, the Cascade AIDS Project. She is an advocate for science education and outreach to the public and frequently speaks both locally and nationally on this subject.
Areas of interest
- HIV and AIDS
- Mother to child transmission of HIV
- Nonhuman primate models for human disease
- Antibody-based therapies for infectious diseases
- Viral vaccines
- Viral pathogenesis and immunity
- Ph.D., University of North Carolina at Chapel Hill United States 1980
- Postdoctoral fellowship, Johns Hopkins University, 1979-1981
Honors and awards
- Fellow of the American Academy of Microbiology
- Australasian Society for Immunology Visiting Speaker
- Cascade AIDS Project 2017 Action Award in recognition of outstanding volunteer service to this AIDS service organization
Memberships and associations
- Associate Editor, Journal of Virology 2000-2016
- Editorial Board, AIDS, 2009-10 and 2016-present
- Office of AIDS Research Advisory Council, 2002-2005
- US-Japan Cooperative Medical Science Program (AIDS panel); retired U.S. Chairman, 2003-10
- Board of Scientific Counselors, NCI, NIH 2006-2008
- Scientific Advisory Committee, International AIDS Vaccine Initiative, 2007-2012
- Council of Councils, NIH 2013-2015
- National Association for Biomedical Research, Executive Board 2013-2016
- Board of Scientific Counselors, Vaccine Research Center, NIAID, NIH 2011-present
Steimer, KS, CJ Scandella, PV Skiles, and NL Haigwood (1991) Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
Igarashi T, C Brown, A Azadegan, N Haigwood, M Martin, and R Shibata. (1999) Human immunodeficiency virus type 1 neutralizing antibodies facilitate clearance of cell-free virions from blood plasma. Nature Medicine 5:211-216.
Shibata R, T Igarashi, N Haigwood, A Buckler-White, R Ogert, W Ross, R. Willey, MW Cho, and MA Martin (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 5:204-210.
Ng CT**, Jaworski JP***, Jayaraman P**, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. (2010) Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Medicine 16(10):1117-9.
Malherbe, D***, N Doria-Rose***, L Misher, T Beckett**, W Blay Puryear***, JT Schuman, Z Kraft, J O’Malley, M Mori, I Srivastava, S Barnett, L Stamatatos and NL Haigwood. (2011) Sequential immunization with a subtype B HIV-1 Envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virology, 85: 5262-74.
JP Jaworski***, Z Brower, EJ Leon, DC Malherbe***, G Landucci, WF Sutton, B Guo, F Engelmann, B Zheng, A Legasse, B Park, M Dickerson, AD Lewis, LMA Colgin, M Axthelm, I Messaoudi, J Kobie, JB Sacha, DR Burton, DN Forthal, AJ Hessell, and NL Haigwood (2013) Passive neutralizing antibodies alter the dynamics of infection and enhance survival of SHIVSF162P3-infected infant rhesus macaques, J Virol 87: 10447-59.
Krebs, SJ***, SP McBurney***, DN Kovarik**, CD Waddell, JP Jaworski***, WF Sutton, MM Gomes***, M Trovato, G Waagmeester, SJ Barnett, P DeBerardinis, NL Haigwood (2014) Multimeric scaffolds displaying the HIV-1 Envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA. PLoS One 9: e113463. PMCID: 4267727.
Hessell AJ, DC Malherbe, F Pissani** SP McBurney***, SJ. Krebs***, M Gomes***, S Pandey, WF Sutton, BJ Burwitz, M Gray, H Robins, B Park, JB Sacha, CC LaBranche, DH Fuller, DC Montefiori, L Stamatatos, DN Sather|, and NL Haigwood (2016) Achieving potent autologous neutralizing antibody responses against Tier 2 HIV-1 viruses by strategic selection of Envelope immunogens, Journal of Immunology 196: 3064-78.
AJ Hessell, JP Jaworski***, E Epson***, K Matsuda, S Pandey, C Kahl, J Reed, WF Sutton, KB Hammond, TA Cheever, PT Barnette, A Legasse, S Planer, J Stanton, A Pegu, X Chen, K Wang, MK Axthelm, A Lewis, VM Hirsch, BS Graham, JR Mascola, JB Sacha, and NL Haigwood (2016) Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Medicine 22: 362-8.
A Pegu, AJ Hessell, JR Mascola, NL Haigwood (2017) Use of broadly neutralizing antibodies for HIV-1 prevention. Immunological Reviews 275 (1), 296-312.
- "Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials." Scientific Reports In: , Vol. 8, No. 1, 18863, 01.12.2018.
- "Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Envspecific antibody response in SHIV-infected rhesus macaques." PLoS ONE In: , Vol. 12, No. 2, e0172524, 01.02.2017.
- "Use of broadly neutralizing antibodies for HIV-1 prevention." Immunological Reviews In: , Vol. 275, No. 1, 01.01.2017, p. 296-312.
- "Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination." Vaccine In: , 18.08.2016.
- "E2 multimeric scaffold for vaccine formulation : Immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells." BMC Microbiology In: , Vol. 16, No. 1, 152, 16.07.2016.
- "Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides." Vaccine In: , Vol. 34, No. 24, 23.05.2016, p. 2713-2721.
- "Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens." Journal of Immunology In: , Vol. 196, No. 7, 01.04.2016, p. 3064-3078.
- "Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques." Nature Medicine In: , Vol. 22, No. 4, 01.04.2016, p. 362-368.
- "Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates." Vaccine In: , 28.11.2015.
- "Animal models in HIV-1 protection and therapy." Current Opinion in HIV and AIDS In: , Vol. 10, No. 3, 27.05.2015, p. 170-176.
- "Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies." Monoclonal Antibodies in Immunodiagnosis and Immunotherapy In: , Vol. 34, No. 2, 01.04.2015, p. 65-72.
- "HIV : Tied down by its own receptor." Nature In: , Vol. 519, No. 7541, 05.03.2015, p. 36-37.
- "Multimeric scaffolds displaying the HIV-1 Envelope mper induce mper-specific antibodies and cross-neutralizing antibodies when Co-Immunized with gp160 DNA." PLoS One In: , Vol. 9, No. 12, e0113463, 01.12.2014.
- "Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity." Pharmaceutical Research In: , Vol. 31, No. 9, 01.09.2014, p. 2393-2403.
- "Improvement of antibody responses by HIV envelope DNA and protein co-immunization." Vaccine In: , Vol. 32, No. 4, 16.01.2014, p. 507-513.
- "Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits." Journal of Virology In: , Vol. 88, No. 22, 2014, p. 12949-12967.
- "Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1." Journal of Virology In: , Vol. 88, No. 22, 2014, p. 12968-12981.
- "HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans." PLoS One In: , Vol. 8, No. 9, e75277, 09.09.2013.
- "SIV infection of rhesus macaques of Chinese origin : A suitable model for HIV infection in humans." Retrovirology In: , Vol. 10, No. 1, 89, 15.08.2013.
- "Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques." Journal of Virology In: , Vol. 87, No. 19, 2013, p. 10447-10459.
- "Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially." Vaccine In: , Vol. 30, No. 37, 10.08.2012, p. 5519-5526.
- "Neutralizing antibodies and control of HIV : Moves and countermoves." Current HIV/AIDS Reports In: , Vol. 9, No. 1, 03.2012, p. 64-72.
- "Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8 + T cells." PLoS One In: , Vol. 7, No. 2, e31464, 16.02.2012.
- "Lessons in nonhuman primate models for AIDS vaccine research : From minefields to milestones." Cold Spring Harbor perspectives in medicine In: , Vol. 2, No. 6, a007310, 2012.
- "Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in Vivo development of neutralizing antibodies." Journal of Virology In: , Vol. 85, No. 11, 06.2011, p. 5262-5274.
- "HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells." Virology In: , Vol. 407, No. 2, 25.11.2010, p. 296-305.
- "Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques." Nature Medicine In: , Vol. 16, No. 10, 10.2010, p. 1117-1119.
- "Host factors involved in the viral replication and particle formation could give a new insight into the innate immunity and may turn out to be a good target for therapeutic intervention. Introduction." Vaccine In: , Vol. 28 Suppl 2, 26.05.2010.
- "Introduction." Vaccine In: , Vol. 28, No. SUPPL. 2, 26.05.2010.
- "P05-10. Sequential immunization with a subtype B HIV-1 envelope quasispecies elicits broader neutralization than vaccination with a single envelope clone." Retrovirology In: , Vol. 6, No. SUPPL. 3, 1742, 22.10.2009.